Wells Fargo stock slides as credit-card cap fight looms — what investors watch next week

Wells Fargo stock slides as credit-card cap fight looms — what investors watch next week

Wells Fargo shares fell 1.2% Friday to $86.96 as investors weighed policy uncertainty and interest rate outlooks. CEO Charlie Scharf warned a 10% cap on credit card rates could sharply reduce credit availability. The bank issued $8 billion in medium-term notes. The Federal Reserve’s rate decision is expected January 28.
Lam Research stock slips before earnings week as Citi cites “Phase 2 upcycle”

Lam Research stock slips before earnings week as Citi cites “Phase 2 upcycle”

Lam Research shares fell 1.3% to $217.94 Friday, extending a two-day slide despite Citi raising its price target to $265. The stock closed about 7.7% below its 52-week high. Investors await Lam’s Jan. 28 earnings and the Federal Reserve’s rate decision next week. Trading volume on Friday was near 10 million shares.
IBM stock price dips into the weekend as investors brace for Jan. 28 earnings

IBM stock price dips into the weekend as investors brace for Jan. 28 earnings

IBM shares fell 0.76% to $292.44 Friday and slipped further after hours ahead of its January 28 earnings report. Investors await fourth-quarter results and guidance, focusing on software and consulting tied to new AI services. IBM Consulting has launched an internal AI delivery platform, but executives warn that scaling real value remains difficult. The company will hold its earnings call Wednesday at 5 p.m. ET.
AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

AstraZeneca stock faces a new test: Iraq terrorism lawsuit revived with NYSE move days away

A U.S. appeals court on Friday revived a lawsuit accusing AstraZeneca and other firms of funding terrorism in Iraq. The ruling was announced after U.S. markets closed; AstraZeneca shares had closed up 1.37% in New York and 0.15% in London. The company plans to switch its U.S. listing from Nasdaq to NYSE on Jan. 30. Investors await Monday’s market reaction.
Morgan Stanley stock slides into weekend as Fed decision, SpaceX IPO talk loom

Morgan Stanley stock slides into weekend as Fed decision, SpaceX IPO talk loom

Morgan Stanley shares fell 2.2% to $179 Friday, underperforming major indexes as bank stocks broadly declined. Goldman Sachs dropped 3.7%, JPMorgan Chase nearly 2%, and Bank of America 1.4%. The S&P 500 was flat, while the Dow lost 0.58%. Investors await the Federal Reserve’s Jan. 28 decision and earnings from Apple, Microsoft, Meta, and Tesla next week.
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B shares closed up 1.17% at 401.35 crowns in Copenhagen, lifted by strong early U.S. demand for its new Wegovy pill. The company faces a new U.S. lawsuit alleging a “pay-for-delay” scheme for Victoza. Over 18,000 Wegovy pill prescriptions were reported in the U.S. since its Jan. 5 launch. Indian regulators approved local firms to make generic semaglutide ahead of the 2026 patent expiry.
StubHub lawsuit deadline just passed: what’s next in the IPO cash-flow class action

StubHub lawsuit deadline just passed: what’s next in the IPO cash-flow class action

The deadline for investors to seek lead plaintiff status in the StubHub IPO securities class action passed Friday, Hagens Berman said. Plaintiffs allege StubHub’s IPO documents failed to disclose a vendor payment delay that impacted free cash flow. StubHub shares closed at $14.70, down 3.8% and well below the $23.50 IPO price. The court will now review motions and set the next steps in the case.

Stock Market Today

SGX share price dips at week’s end after record profit; what investors watch next

SGX share price dips at week’s end after record profit; what investors watch next

7 February 2026
Singapore Exchange shares closed 0.4% lower at S$17.57 on Friday, despite reporting record half-year results and a higher dividend earlier in the week. Broker targets diverged after the update, with Maybank and DBS raising targets while Citi stayed bearish. Investors are watching for signs of momentum from derivatives and equity-market reforms as the next session opens Monday.
South32 share price drops 4% in ASX rout — what investors watch before results

South32 share price drops 4% in ASX rout — what investors watch before results

7 February 2026
South32 shares fell 4.1% to A$4.41 Friday as Australian miners dropped in the worst ASX session since April 2025. The S&P/ASX 200 lost 2%, erasing almost A$70 billion in value. South32’s half-year results and interim dividend decision are set for Feb. 12. Markets reopen Monday with investors watching for further volatility.
Go toTop